INFLUENZA CVD 15000: EVALUATION OF A BOOSTER DOSE OF A/VIETNAM/1203/04 (H5N1)

流感 CVD 15000：A/VIETNAM/1203/04 (H5N1) 加强剂量的评估

• 批准号: 7608155
• 负责人: JAMES D CAMPBELL
• 金额: $ 3.37万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608155
• 关键词: Avian Influenza; Avian Influenza A Virus; Bird Flu vaccine; Computer Retrieval of Information on Scientific Projects Database; Dose; Evaluation; Funding; Grant; Influenza; Influenza A Virus, H5N1 Subtype; Institution; Research; Research Personnel; Resources; Source; Testing; United States; United States Food and Drug Administration; United States National Institutes of Health; Vaccines; Vietnam; influenza virus vaccine; research study; volunteer

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Volunteers previously took part in a research study to test an experimental vaccine against the A/H5N1 bird flu virus and are now being asked if they would like to take part in an extension study. As part of the original study, they received two doses of the A/H5N1 bird flu vaccine.In the new study volunteers will receive a third dose (booster) at the same dose level as the original study.The vaccine, which is made by sanofi pasteur, Inc. (previously known as Aventis Pasteur, Inc.), is made the same way that the "regular flu" vaccine is made. The A/H5N1 bird flu vaccine is not yet approved by the Food and Drug Administration for use in the United States.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 志愿者先前参加了一项研究，以测试针对A/H5 N1禽流感病毒的实验性疫苗，现在他们被问到是否愿意参加一项扩展研究。作为最初研究的一部分，他们接种了两剂A/H5 N1禽流感疫苗。在新的研究中，志愿者将接种第三剂（加强剂），剂量水平与最初研究相同。疫苗由赛诺菲巴斯德公司生产。（以前称为Aventis Pasteur，Inc.），和“普通流感”疫苗的制作方法一样。美国食品和药物管理局尚未批准A/H5 N1禽流感疫苗在美国使用。